Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

bispecific ligand-drug conjugate CBP-1018

A bispecific ligand-drug conjugate targeting two as of yet undisclosed receptors and conjugated to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon administration of bispecific ligand-drug conjugate CBP-1018, the bispecific ligand moiety targets and binds to one or both of the two as of yet undisclosed receptors expressed in certain tumor types. After internalization of the agent, the cytotoxic moiety is released and kills the cancer cells expressing the receptor(s), through an as of yet unknown mechanism of action.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Code name:	CBP 1018 CBP-1018 CBP1018

bispecific ligand-drug conjugate CBP-1018

Search NCI's Drug Dictionary